GEN1029 (HexaBody -DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

  • STATUS
    Recruiting
  • days left to enroll
    55
  • participants needed
    520
  • sponsor
    Genmab
Updated on 16 January 2022
renal function
cancer
measurable disease
metastasis
solid tumour
metastatic cancer
renal function tests
renal function test
kidney function test

Summary

The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody-DR5/DR5) in a mixed population of patients with specified solid tumors

Description

The trial is an open-label, multi-center safety trial of GEN1029 (HexaBody-DR5/DR5). The trial consists of two parts a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Details
Condition Vaginal Atrophy, Pancreatic Cancer, Gastric Carcinoma, Kidney Cancer, Triple Negative Breast Cancer, Stomach Cancer, Digestive System Neoplasms, Primary Immunodeficiency, Chronic Diarrhea, Renal Cancer, Renal Cell Cancer, Islet Ce417ll Cancer, clear cell renal cell carcinoma, Pancreatic disorder, Colon Cancer Screening, Recurrent Respiratory Papillomatosis, Rectal Disorders, Pancreatic Disorders, Breast Cancer, Pediatric Health, Skin Wounds, nsclc, Diet and Nutrition, cancer of the pancreas, pancreatic cancers, Injection Port, Razor Bumps (Pseudofolliculitis Barbae), Breast Cancer - HER2 Positive, Non-Small Cell Lung Cancer, Stomach Discomfort, cancer, pancreatic, Rectal disorder, Colon cancer; rectal cancer, Adverse Effects, Drugs, Malignant Adenoma, Gastropathy, colorectal tumor, cancer, colorectal, Renal Cell Carcinoma, Anal Dysplasia, Urothelial Cancer, colorectal cancers, gastric cancers, Brain Function, tumors, colorectal, Metastatic Triple-Negative Breast Cancer, Peripheral Arterial Occlusive Disease, colorectal neoplasm, Neoplasm of unspecified nature of digestive system, Adenocarcinoma, Chronic Shoulder Pain, Near-Sighted Corrective Surgery, Colorectal Cancer, Malignant neoplasm of kidney, Gastric Cancer
Treatment GEN1029 (HexaBody®-DR5/DR5)
Clinical Study IdentifierNCT03576131
SponsorGenmab
Last Modified on16 January 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note